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The mitochondrial membrane protein termed ‘‘mitoNEET,’’ is a putative secondary target for insulin-sensitizing thiazolid-
inedione (TZD) compounds but its role in regulating metabolic ﬂux is not known. PNU-91325 is a thiazolidinedione derivative
which exhibits high binding afﬁnity to mitoNEET and lowers cholesterol, fatty acid and blood glucose levels in animal models. In
this study we report the stable isotope-based dynamic metabolic proﬁles (SIDMAP) of rosiglitazone, pioglitazone and PNU-91325
in a dose-matching, dose-escalating study. One and 10 lM concentrations 1 and 10 lM drug concentrations were introduced into
HepG2 cells in the presence of either [1,2)13C2]-D-glucose or [U)
13C18]stearate, GC/MS used to determine positional tracer
incorporation (mass isotopomer analysis) into multiple metabolites produced by the Krebs and pentose cycles, de novo fatty acid
synthesis, long chain fatty acid oxidation, chain shortening and elongation. Rosiglitazone and pioglitazone (10 lM) increased
pentose synthesis from [U)13C18]stearate by 127% and 185%, respectively, while PNU-91325 rather increased glutamate synthesis
in the Krebs cycle by 113% as compared to control vehicle treated cells. PNU-91325 also increased stearate chain shortening into
palmitate by 59%. Glucose tracer-derived de novo palmitate and stearate synthesis were increased by 1 and 10 lM rosiglitazone by
41% and 83%, respectively, and by 63% and 75% by PNU-91325. Stearate uptake was also increased by 10 lM PNU-91325 by
15.8%. We conclude that the entry of acetyl Co-A derived from long-chain fatty acid b-oxidation into the mitochondria is
facilitated by the mitoNEET ligand PNU-91325, which increases glucose-derived long chain fatty acid synthesis and breakdown via
b-oxidation and anaplerosis in the mitochondria.
KEY WORDS: PNU-91325; mitoNEET; stable isotope-based dynamic metabolic proﬁling (SIDMAP); fatty acid oxidation;
glucose metabolism; diabetes.
1. Introduction
Thiazolidinedione (TZD) compounds are used for the
treatment of type 2 diabetes and are believed to exert their
beneﬁcial eﬀects by increasing glucose-derived fatty acid
synthesis secondary to the increased degradation of long
chain fatty acids through the activation of the nuclear
receptor peroxisome proliferator-activated receptor-
gamma (PPARc). Studies with a tritiated photo-aﬃnity
labeled pioglitazone (1)
analog identiﬁed a novel saturable TZD binding site also
in mitochondria (Colca et al., 2004). The binding corre-
lated with a <17-kDa protein, which showed selectivity
of competition by analogs. The protein is termed
‘‘mitoNEET,’’ and has been found in the mitochondrial
fraction of rodent brain, liver, and skeletal muscle. The
protein also exists in low levels in preadipocytes, but
expression increases exponentially in diﬀerentiated
adipocytes (Colca et al., 2004).
Several pioglitazone (1) derivatives have been tested
as antidiabetic TZDs for possible clinical development
(Tanis et al., 1996). PNU-91325 (2)
was found to be the most eﬀective TZD and proved to
have greater binding to mitoNEET. Thus modiﬁcation
of mitoNEET function may, at least in part, contribute
to lowering circulating lipid levels and glucose in the
KKAy mouse model of human type-2 diabetes. Evidence
has recently been presented suggesting that the insulin
sensitizing eﬀects of thiazolidinediones may correlate
with modiﬁcation of mitochondrial function rather
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than activation of PPARc (Colca, 2006). Changes in
mitochondrial function may alter the usage of cellular
metabolites (e.g., sugars and fatty acids) in a way that
favors insulin sensitivity.
In this study we report the stable isotope-based
dynamic metabolic proﬁle (SIDMAP) of rosiglitazone (3),
pioglitazone (1) and PNU-91325 (2) in a dose-matching,
dose-escalating in vitro study. In order to follow sub-
strate ﬂow in the glucose metabolic network and the fate
of the long chain fatty acid derived acyl-CoA we used
two tracers; [1,2)13C2]-D-glucose or [U)
13C18] stearate
pool in diﬀerentiated primary hepatocellular carcinoma
(HepG2) cells and gas chromatography/mass spec-
trometry (GC/MS) to analyze RNA ribose synthesis,
lactate production, TCA cycle glutamate synthesis, as
well as myristate, palmitate, stearate and oleate syn-
thesis and turnover using the comprehensive multiple
pathway tracer substrate ﬂow analysis platform of the
SIDMAParray (Boros et al., 2004). It is herein demon-
strated that PNU-91325 (2) potently increases de novo
long chain fatty acid synthesis from glucose, while it also
increases mitochondrial breakdown of long-chain
derived acyl-CoA via TCA cycle anaplerosis and gluta-
mate synthesis. On the contrary, rosiglitazone (3) and
pioglitazone (1) are more eﬀective in re-routing stearate
derived acyl-CoA towards glyconeogenesis and the
synthesis of ﬁve carbon metabolites such as ribose in the
pentose cycle. We conclude that the mitoNEET protein
is a secondary TZD target and has a role in increasing
mitochondrial long chain fatty acid derived acyl-CoA
disposal through TCA cycle anaplerosis.
2. Materials and methods
Two non-radiating stable isotope tracer carbon
labeled substrates were used in this metabolic ﬂux
analysis study: (a) [1,2)13C2]-D-glucose was purchased
with >99% purity and 99% isotope enrichment for
each position from Cambridge Isotope Laboratories,
Inc. (Andover, MA, USA); and (b) [U)13C18]-stearic
acid (Spectra Stable Isotopes, Spectra Gases Inc.,
Branchburg, NJ). Rosiglitazone (3), pioglitazone (1) and
PNU-91325 (2) were provided by Pﬁzer, Inc., under a
material transfer agreement.
2.1. Cells and cell culture
Human liver hepatocellular (epithelial) carcinoma
HepG2 cells (ATCC CRL11997) were purchased from
American Type Culture Collection (ATCC, Manassas,
VA, USA). HepG2 cells have an average doubling time
of 34 h in DMEM with 10% fetal bovine serum and
2.5% horse serum (Gibco/BRL, Gaitersburg, MD) in
the presence of antibiotics. The cells were incubated at
37 C, 5% CO2 and 95% humidity and passed by using
trypsin 0.25% (Gibco/BRL) no more than three times
after receipt from the ATCC and prior to use in this
study. HepG2 cells have previously been used in both in
vitro and in vivo experiments and responded to treat-
ment with troglitazone and other compounds with
characteristic metabolic proﬁle changes showing altered
macromolecule synthesis and fatty acid cycling (Lee
et al., 1998a). Tracer-labeled parallel cultures of HepG2
cells were used in this study as controls to compare
vehicle (DMSO) treated cell cultures to rosiglitazone (3),
pioglitazone (1) and PNU-91325 (2) treatment in an
escalating regime of drug treatment.
Seventy-ﬁve percent conﬂuent cultures of HepG2
cells were incubated in either [1,2)13C2]-D-glucose or
[U)13C18]stearate-containing media (100 mg/dl total
glucose concentration=5 mM; 50% isotope enrich-
ment; or 0.5 mM uniformly labeled stearate). Cells were
plated at a density of 106 per T75 culture ﬂask and
rosiglitazone (3), pioglitazone (1) and PNU-91325 (2)
were added in two concentrations, 1 or 10 lM dissolved
in 10% DMSO – 90% culture media. Control cultures
were treated with vehicle (10% DMSO) only. The doses
of rosiglitazone (3), pioglitazone (1) and PNU-91325 (2)
for the present study were selected based on in vitro
experiments demonstrating that these drugs eﬀectively
control glucose levels via PPARc activation in various
human cell culture systems in the 1 to a 10 lM dose
range (for review: Otto et al., 2002). Drug treatments
were carried out for 72 h in the presence of each tracer.
Glucose and U-stearate 13C tracer levels in the medium
were monitored using a Cobas Mira chemistry analyzer
(Roche Diagnostics, Pleasanton, CA, USA). Fresh,
tracer enriched culture medium and drug treatments
were applied every 24 h, three times during the experi-
ment, in order to provide for the cells with steady tracer-
enriched medium and drug doses throughout the 72 h
experimental period. After 72 h the cells were scraped,
spun and frozen at )80C until further processing as
described below.
2.2. RNA ribose stable isotope studies
For mass isotopomer analysis RNA ribose was iso-
lated by acid hydrolysis of cellular RNA after Trizol
(Invitrogen Life Technologies, Carlsbad, CA, USA)
extraction from the cell pellets. Ribose was derivatized
to its aldonitrile acetate form using hydroxylamine in
pyridine with acetic anhydride (Supelco, Bellefonte, PA,
USA) before mass spectral analyses. We monitored the
ion cluster around the m/z256 (carbons 1–5 of ribose)
(chemical ionization, CI) and m/z217 (carbons 3–5 of
ribose) and m/z242 (carbons 1–4 of ribose) (electron
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impact ionization, EI) to determine molar enrichment
and the positional distribution of 13C in ribose. By
convention, the base mass of 12C compounds (with their
derivatization agents) is given as m0 as measured by
mass spectrometry as described elsewhere (Katz et al.,
1993). Ribose molecules labeled with a single 13C atom
on the ﬁrst carbon position (m1) recovered from RNA
were used to gauge the ribose fraction produced by
direct oxidation of glucose through the G6PD pathway.
Ribose molecules labeled with 13C on the ﬁrst two
carbon positions (m2) were used to measure the fraction
produced by transketolase. Doubly labeled ribose mol-
ecules (m2 and m4) on the fourth and ﬁfth carbon
positions were used to measure molar fraction produced
by triose phosphate isomerase and transketolase (Boros
et al., 2002). Because transketolase has the highest
metabolic control coeﬃcient in the non-oxidative
branch of the pentose cycle (Sabate et al., 1995), we use
the term transketolase throughout the paper. It should
be noted, though, that transketolase and transaldolase,
besides other enzymes, all are participants in non-oxi-
dative pentose cycle metabolism in human cells.
2.3. Lactate
Lactate from the cell culture media (0.2 ml) was
extracted by ethylene chloride after acidiﬁcation with
HCl. Lactate was derivatized to its propylamine-hepta-
ﬂuorobutyrate ester form and the m/z328 (carbons 1–3
of lactate) (chemical ionization, CI) was monitored for
the detection of m1 (recycled lactate through the PC)
and m2 (lactate produced by the Embden–Meyerhof–
Parnas pathway) for the estimation of pentose cycle
activity (Lee et al., 1998b). In this study we recorded the
m1/m2 ratios in lactate produced and released by HepG2
cells in order to determine pentose cycle activity and
pentose cycling versus anaerobic glycolysis in response
to 1 and 10 lM rosiglitazone (3), pioglitazone (1) and
PNU-91325 (2) treatments.
2.4. Glutamate
13C label distribution in glutamate (glutamic acid),
which is synthesized from a-keto-glutaric acid of the
TCA cycle, from tracer labeled glucose or stearate is
suitable for determining mitochondrial glucose and fatty
acid disposal via anabolic substrate use within the cycle,
also known as anaplerotic ﬂux. For glutamate extraction
tissue culture medium (1 ml) was ﬁrst treated with 1 ml
of 6% perchloric acid and the supernatant was passed
through a 3 cm3 Dowex-50 (H+) column. Amino acids
were eluted with 15 ml 2 N ammonium hydroxide. In
order to separate glutamate from glutamine, the amino
acid mixture was passed through a 3 cm3 Dowex-1
(acetate) column, and then collected with 15 ml 0.5 N
acetic acid. The glutamate fraction from the culture
medium was converted to its triﬂuoroacetyl butyl ester
(TAB) (Leimer et al., 1977). Under EI conditions, ion-
ization of TAB-glutamate produces two fragments, m/
z198 and m/z152, corresponding to C2–C5 and C2–C4
of glutamate. Glutamate labeled on the 4–5 carbon
positions indicates pyruvate dehydrogenase activity
while glutamate labeled on the 2–3 carbon positions
indicates pyruvate carboxylase activity for the entry of
glucose carbons to the TCA cycle. TCA cycle anabolic
glucose utilization is calculated based on the m1/m2
ratios of glutamate (Lee et al., 1996).
2.5. Lipid extraction and analysis
Lipid extractions were performed using methods
described elsewhere (Lowenstein et al., 1975). In brief,
the Trizol extract (bottom layer) of cell pellets after
RNA extraction were saponiﬁed with 500 ll of 30%
KOH–ethanol (1:1 v/v) at 70 C overnight. The aqueous
phase was acidiﬁed, and fatty acids were extracted in
petroleum ether and dried under a stream of nitrogen.
Fatty acids were methylated with 0.5 ml 0.5 N HCl in
methanol for GC/MS analysis. Palmitate, stearate and
oleate were monitored at m/z270, m/z298 and m/z264,
respectively, with the enrichment of 13C labeled acetyl
units either from tracer labeled glucose or stearate,
which reﬂect synthesis, elongation and desaturation of
the new lipid fraction as determined by mass isotopomer
distribution analysis (MIDA) of diﬀerent isotopomers
(Lee et al., 1991). Mass isotopomer distribution was
determined using the method of Lee et al., which cor-
rects for the contribution of derivatizing agent and 13C
natural abundance to the mass isotopomer distribution
of the compound of interest. The calculated mass iso-
topomer distribution is expressed as molar fractions
(m0, m1, m2, m3, etc.), which are the fractions of mol-
ecules containing 0, 1, 2, 3,... 13C substitutions, respec-
tively. Data reduction and regression analyses were
performed using the computer software Microsoft
Excel version 5.0.
2.5.1. Determination of precursor enrichment
b-oxidation of [U)13C18]stearate generates [1,2)
13C2]
acetyl-CoA, which is subsequently used as a precursor
for de novo lipogenesis, chain elongation, energy pro-
duction and anaplerosis via the tricarboxylic acid cycle.
Thus, b-oxidation can be assessed through the deter-
mination of [1,2)13C2]acetyl-CoA enrichment in the
diﬀerent synthetic products.
2.5.2. Acetyl-CoA enrichment for de novo synthesis
from glucose
The enrichment of the cytosolic acetyl-CoA pool used
in de novo fatty acid synthesis was determined from the
mass isotopomer distribution in palmitate and stearate
using the [1,2)13C2]-D-glucose as the tracer. De novo
synthesis produces these long chain saturated fatty acids
with 2, 4, or 6 13C atoms (m2, m4, and m6). The
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distribution of these mass isotopomers has been previ-
ously shown to be a binomial distribution (Hellerstein,
1991; Lee et al., 1992). Thus, the acetyl-CoA enrichment
may be obtained from the consecutive mass isotopomer
ratio m4/m2=(n)1)p/q=3.5p/q, where n is the number
of acetyl units in palmitate=8, p is the enrichment of
[1,2)13C2]acetyl-CoA, q is the unenriched acetyl-CoA,
and p+q=1.
2.5.3. Acetyl-CoA enrichment from mitochondrial
oxidation
[1,2)13C2]acetyl-CoA produced either from [1,2)
13C2]-
D-glucose or [U)13C18]stearate from b-oxidation com-
bines with oxaloacetic acid and forms citric acid in the
mitochondria. Citrate participates in the tricarboxylic
acid cycle, eventually forming [a-4,5)13C2]ketoglutarate
and glutamate (Haber and Lapidot, 2001). The enrich-
ment of the m2 component of the C2–C5 fragment
generally reﬂects tricarboxylic acid cycle activity. How-
ever, it is well known that contribution from unlabeled
glutamate from the cells in culture with glutamine-con-
taining medium can substantially dilute the glutamate
enrichment (Darmaun et al., 1988). Therefore, the
enrichment of the [4,5)13C2]glutamate reﬂects the lower
limit of mitochondrial acetyl-CoA cycling and anaplerosis.
2.5.4. Acetyl-CoA enrichment for chain elongation
Enzymes involved in chain elongation from
[U)13C18]stearate to longer chain fatty acids are located
in the endoplasmic reticulum, mitochondria, and per-
oxisomes (Vance and Vance, 2002). Chain elongation of
uniformly labeled stearate with [1,2)13C2]acetyl-CoA
produces characteristic m+18 clusters that can be used
to determine the acetyl-CoA enrichment according to
the rules of combination of two labeled precursors. The
ratio of m+2 to m+0 acetyl-CoA for chain elongation
is given by the ratio of m+20 to m+18 in arachidate
using the [U)13C18]stearate tracer. The enrichment of
[1,2)13C2]acetyl-CoA for each step of chain elongation
was determined using the method described elsewhere
using HepG2 cells as the in vitro model of fatty acid
metabolism in the presence of [U)13C18]stearate (Wong
et al., 2004).
2.6. Gas chromatography/mass spectrometry (GC/MS)
Mass spectral data were obtained on the HP5973
mass selective detector connected to an HP6890 gas
chromatograph. The settings were as follows: GC inlet
250 C, transfer line 280 C, MS source 230 C, MS
Quad 150 C. An HP-5 capillary column (30 m length,
250 lm diameter, 0.25 lm ﬁlm thickness) was used for
glucose, ribose, deoxyribose, glutamate and lactate
analyses. Alternatively, a Bpx70 column (25 m length,
220 lm diameter, 0.25 lm ﬁlm thickness, SGE Incor-
porated, Austin, TX) was used for fatty acid analysis
with speciﬁc temperature programming for myristate
(C:14), palmitate (C:16), stearate (C:18), oleate (C:18–
1), as well as C:20, C:22 and C:24 fatty acid analyses.
2.7. Data analysis and statistical methods
Each experiment was carried out using triplicate cell
cultures for each condition within each experiment and
experiments were repeated once. Mass spectroscopic
analyses were carried out by three independent auto-
matic injections of 1 ll samples by the automatic sampler
and accepted only if the standard sample deviation was
less than 1% of the normalized peak intensity. Statistical
analysis was performed using the Student’s t-test for
unpaired samples. Two-tailed signiﬁcance at the 99%
conﬁdence interval (l±2.58 r), p<0.01 indicated sig-
niﬁcant diﬀerences in glucose carbon metabolism in
control and rosiglitazone (3), pioglitazone (1) and PNU-
91325 (2) treated HepG2 cells. SIDMAParrayTM was
produced by MeTa Informatics (San Diego, CA).
3. Results
In this study the stable isotope-based metabolic pro-
ﬁles of rosiglitazone (3), pioglitazone (1) and PNU-
91325 (2) treated HepG2 cells are presented using two
tracers, [1,2)13C2]-D-glucose and [U)
13C18]stearic acid
in separate experiments. The metabolic proﬁles reported
in the SIDMAParrays present tracer carbon ﬂow
changes in all major metabolic pathways, which include
glycolysis, the pentose and TCA cycles, de novo fatty
acid synthesis, chain elongation, chain shortening and
desaturation, in a color scheme similar to gene expres-
sion studies.
The SIDMAParray using the [1,2)13C2]-D-glucose
tracer is shown in ﬁgure 1. It can be seen from the array
represented in ﬁgure 1 that rosiglitazone (3) and PNU-
91325 (2) induced a signiﬁcant increase in de novo fatty
acid synthesis from glucose, including myristate, palm-
itate and stearate (box 3), while substrate ﬂux through
the pentose cycle producing ribose and deoxyribose were
less aﬀected by either drug (boxes 1 & 2). Rosiglitazone
(3) and PNU-91325 (2) increased de novo stearate syn-
thesis from glucose by 41% and 83% and by 63% and
75% using 1 and 10 lM doses, respectively. It can also
be seen from the array that all compounds increased
glucose-derived acetyl-CoA 13C enrichment of myristate
and stearate. There were no signiﬁcant changes in pen-
tose cycle direct glucose oxidation and recycling into
lactate or TCA cycle anaplerotic ﬂux for the synthesis of
glutamate from glucose (data not shown). It can be
concluded from the array that 1 and 10 lM rosiglitaz-
one (3) and PNU-91325 (2) induced similar changes in
glucose carbon utilization in HepG2 cells, which was
consistent with increased de novo long chain fatty acid
synthesis from glucose, with little or no eﬀect on the rate
of glucose oxidation (13CO2 release in the TCA and
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pentose cycles), or de novo ribose and deoxyribose
synthesis in the pentose cycle. Ten lM pioglitazone (1)
was also eﬀective in increasing de novo stearate synthesis
from glucose by about 30% of control cells.
There were more characteristic and obvious diﬀer-
ences in how rosiglitazone (3), pioglitazone (1) and
PNU-91325 (2) aﬀected uniformly labeled stearate
synthesis as ﬁgure 1.
The main diﬀerence in stearate utilization among
the drugs is that 1 and 10 lM rosiglitazone (3) and
pioglitazone (1) induced a dose dependent increase in
pentose cycle ribose 13C enrichment by 101%, 127%
and 250%, 285% (box 1), while 1 and 10 lM PNU-
91325 rather increased mitochondrial TCA cycle
glutamate synthesis from stearate by 25% and 113%
(box 2), respectively. Glutamate 13C enrichment from
stearate was only increased using 10 lM rosiglitazone
(3) or pioglitazone (1) by 22% and 21%, respectively.
It appeared that the primary route by which stearate
13C tracer carbons entered the TCA cycle is via
citrate synthesis, as 10 lM pioglitazone (2) and PNU-
91325 (1) induced a 12% and 34% increase in glu-
tamate synthesis via citrate (box 3). De novo palmitate
synthesis from stearate-derived [13C2]acetyl-CoA was
increased by 102%, while stearate chain shortening
into palmitate was also increased by 59% using
10 lM PNU-91325 (box 4). Stearate uptake and
chain elongation into arachidonic acid was also
increased by 10 lM PNU-91325 by 16% and 8%,
respectively (box 6).
Interestingly, the 13C labeled fraction of deoxyribose
(DOR) of DNA from stearate was decreased by 20% and
37% and total 13C enrichment of DOR was also strongly
inhibited by 24% and 45% using 1 and 10 lM PNU-
91325 (box 6). On the other hand, there was no signiﬁ-
cant inhibition of deoxyribose synthesis from stearate by
rosiglitazone (3) or pioglitazone (1) in the 72 h study
period. There was about 10% increase in lactate 13C
enrichment from stearate using 1 lM rosiglitazone (3)
only, indicating that stearate derived acetyl-CoA
disposal via lactate is not a signiﬁcant route imposed by
either drug.
4. Discussion
Metabolic proﬁling represents a logical development
in the application of genomics, transcriptomics and
proteomics in drug discovery and development. This
study highlighted the relevance and robustness of
stable isotope tracer-based dynamic metabolic proﬁles
when applied to drugs discovered through reverse
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Figure 1. Stable isotope-based dynamic metabolic proﬁle array (SIDMAParray) of rosiglitazone, pioglitazone and PNU-91325 in HepG2 cells
using [1,2)13 C2]-D-glucose as the tracer. Treatments are indicated as follows: C=Control; 1R=1 lM rosiglitazone; 10R=10 lM rosiglitazone;
1P=1 lM pioglitazone; 10P=10 lM pioglitazone; 1PN=1 lM PNU-91325; and 10PN=10 lM PNU-91325. The color of each square
corresponds to 13C tracer glucose ﬂux via various synthetic pathways of ribose, deoxyribose and fatty acids as percent of control-DMSO treated
cultures. A color scheme indicating the intensity of changes in substrate ﬂux is provided in the bottom of the ﬁgure. Signiﬁcant increase in de novo
fatty acid synthesis from glucose are underlined and italicized (G6PDH=glucose 6-phosphate dehydrogenase; TPI=Triose-phosphate
isomerase).
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pharmacology (Harrigan et al., 2005). This study makes
used of continued development of new approaches to
generate and interrogate metabolome data sets. Here we
have evaluated three thiazolidinediones that exhibit
overall similar insulin sensitizing pharmacology in vivo
but vary substantially in their ability to activate the
transcription factor PPARc. This study determined
glucose and stearate ﬂow redistribution among major
metabolic pathways involving glycolysis, the pentose
and TCA cycles, de novo fatty acid synthesis and deg-
radation in response these three thiazolodinediones in
living HepG2 primary liver tumor cells. The compounds
tested in this study include two drugs marketed for the
treatment of diabetes and a third analog that has potent
insulin sensitizing activity without activating PPARc-
regulated gene transcription (Colca, 2006). Gene tran-
scription analysis from earlier studies suggests that
changes the expression of mitochondrial proteins might
be a key factor in the insulin sensitizing pharmacology.
Our ﬁndings using glucose as a metabolic tracer are that
rosiglitazone (3), pioglitazone (1) and PNU-91325 (2)
increase de novo synthesis of various fatty acids from
glucose, and that PNU-91325 (2) surpasses the eﬀect of
both marketed drugs. Using stearate as a metabolic
tracer it is obvious that rosiglitazone (3) and pioglitaz-
one (1) primarily induce fatty acid breakdown by
increasing glyconeogenesis and RNA pentose synthesis,
while PNU-91325 (2) forces stearate-derived acetyl units
into the mitochondria via citrate synthesis in a dose
dependent manner.
The main implication of our SIDMAP study is that
predominantly PPARc and predominantly mitochond-
rially acting (mitoNEET ligand) compounds direct long
chain fatty acid catabolism into diﬀerent routes. PNU-
91325 (2) is very eﬀective in promoting mitochondrial
stearate b-oxidation, while concomitantly increasing
stearic acid uptake, chain shortening into palmitate and
chain elongation into arachidonate. On the other hand,
rosiglitazone (3) and pioglitazone (1) primarily increase
pentose sugar synthesis from stearate, which indicates
peroxisomal fatty acid metabolism and the production
of acyl-CoA, which may enter the mitochondria and
produce glutamate, but only at the high 10.0 lM dose in
this dose matching study with PNU-91325. The potency
of PNU-91325 (2) in increasing mitochondrial beta-
oxidation of stearate and its disposal via glutamate is
about 10 times higher than that of rosiglitazone (3) and
pioglitazone (1). In previous in vivo experiments high
resolution 2-D gel electrophoresis of livers showed that
rosiglitazone (3) primarily produced changes in the
expression pattern of many proteins involved in perox-
isomal fatty acid b-oxidation (Edvardsson et al., 1999).
Although rosiglitazone (3) and PNU-91325 (2) tend to
increase the expression of many mitochondrial proteins
and produce changes that favor fatty acid oxidation,
PNU-91325 (2) does not signiﬁcantly increase PPARc-
driven transcription either in vitro or in vivo (Colca,
2006). The most likely explanation for the eﬀects of
these compounds on gene expression and on the meta-
bolic ﬂuxes observed in these studies is that the overall
eﬀect of a given analog represents a blend of direct
mitochondrial actions (e.g., binding to mitoNEET) and
eﬀects on other sites of binding (e.g., PPARc).
It has been demonstrated that both PPARc ligands
investigated in this study, pioglitazone (1) and rosiglit-
azone (3) eﬀectively decreased liver cancer formation
using a diethylnitrosamine-induced liver cancer in Wi-
star rats (Guo et al., 2004) and colon carcinogenesis
induced by azoxymethane in mice (Osawa et al., 2003).
In our substrate ﬂow tracer study, while rosiglitazone (3)
and pioglitazone (1) increased RNA pentose synthesis
from stearate, there was a decrease in tracer accumula-
tion into DNA deoxyribose during the 72 h treatment
period using these TZDs. On the other hand, DNA
deoxyribose synthesis was strongly suppressed by PNU-
91325 (2) treatment from stearate. The glucose tracer
study indicated unaltered rate of RNA and DNA ribose
synthesis, which conﬁrms the chemo-preventive eﬀect of
TZD based on direct substrate ﬂow measurements via
all arms of the pentose cycle.
We acknowledge two potential limitations of this
study. First, because we studied primary hepatoma cells,
it is not known how the studied compounds aﬀect nor-
mal liver cell function and other tissue cells in a complex
host. It is important to note that HepG2 cells grow
rapidly in culture and they have higher specialized
requirements for energy and macromolecule synthesis
than primary cells. Conditions to test primary liver cells
are under development. Metabolic labeling studies with
primary cells are complicated by the fact that freshly
isolated hepatocytes survive for 24 h providing limited
time to produce a comprehensive SIDMAParray using
either glucose or fatty acid tracers. In any case, HepG2
cells have maintained biotransformation properties of
drugs and they also posses and express metabolic
enzymes in a comparable manner with primary cultures
of hepatocytes (Wilkening et al., 2003), while providing
a highly viable and stable cell line for continuous tracer
based metabolomics studies.
Second, it is currently not known what primary acyl-
CoA species are produced from the tracer stearate
substrate in response to the PPARc agonist rosiglitazone
(3) and pioglitazone (1) treatments. Based on assessing
heavy incorporation of tracer carbons of stearate into
the ﬁve carbon metabolite pool of ribose with no mea-
surable tracer accumulation in lactate or palmitate it is
likely that short chain fatty acids (C:4–C:6) are heavily
produced and shuttled into the cytosol of HepG2 cells
from the peroxisomes. As the use of C18–C20 chain
elongation and other mass isotopomer analysis is the
ﬁrst quantitative method to determine peroxisomal
acetyl-CoA enrichment (and therefore peroxisomal
b-oxidation) (Wong et al., 2004), we will be able to
identify those acyl-CoA pools in subsequent SIDMAP
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studies. Such studies should make use of the tracer
method for both peroxisomal oxidation and very long
chain fatty acid synthesis in HepG2 cell cultures toge-
ther with animal experiments.
It is a particularly signiﬁcant ﬁnding that rosiglit-
azone (3) and pioglitazone (1) treatments strongly
increase pentose formation from tracer stearate,
thereby increasing NADPH production and peroxi-
somal function. In the mammalian liver many b- and
per-oxidation related events require NADPH as the
reducing equivalent. For example, peroxisomal b-oxi-
dation produces hydrogen peroxide. Although hydro-
gen peroxide is not itself a radical, it is considered a
reactive oxygen species because it is easily converted
into hydroxyl radical, which has to be scavenged by
NADPH-dependent reductases thus preventing cell
damage. NADPH-dependent peroxidases are also
important in the microsomal function of liver cells,
therefore, increased carbon ﬂow by rosiglitazone (3)
and pioglitazone (1) towards the pentose cycle are
expected during increased peroxisomal and microsomal
fatty acid degradation (ﬁgure 2). In this paper we show
direct evidence via net tracer carbon ﬂow measure-
ments from stearate towards pentoses that such link
exists and such PPARc ligands concomitantly increase
peroxisomal degradation and pentose cycle metabolism
in the same cells. These diﬀerences in metabolic ﬂux
from those produced by PNU-91325 (2) suggest that
there will be some diﬀerences in the pharmacology
produced by compounds that lack inherent PPARc-like
activity.
In summary, we evaluated glucose and fatty acid
metabolism based on two separate metabolic tracer
substrate experiments using cultured human primary
liver carcinoma cells. Whatever the genetic and proteo-
mic mechanisms are in the complex array of genes and
proteins altered by TZDs, PNU-91325 (2) unquestion-
ably generates a dramatically diﬀerent substrate ﬂow
proﬁle from the long chain fatty stearate than do ros-
iglitazone (3) and pioglitazone (1). PNU-91325 (2)
directs b-oxidation of stearate and chain shortening by
one acetyl unit resulting palmitate, then this acetyl unit
participates in chain elongation and TCA cycle gluta-
mate synthesis. Rosiglitazone (3) and pioglitazone (1)
rather produce short chain fatty acids and their short-
ening is strongly linked with pentose synthesis (ﬁgure 3).
Based on our current ﬁndings, PNU-91325 (2) is a
more potent inducer of mitochondrial fatty acid b-oxi-
dation and TCA cycle anaplerosis than are the existing
compounds to treat hyperlipidemic conditions in type 2
diabetes with desirable anti-proliferative eﬀects and
limited DNA deoxyribose synthesis in liver cells.
In order to reveal organ and tissue speciﬁc metabolic
changes involving liver, muscle, adipose and other
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Figure 2. Stable isotope-based dynamic metabolic proﬁle array (SIDMAParray) of rosiglitazone, pioglitazone and PNU-91325 in HepG2 cells
using [U)13 C18]stearic acid as the tracer. Treatments are indicated as follows: C=Control; 1R=1 lM rosiglitazone; 10R=10 lM rosiglitazone;
1P=1 lM pioglitazone; 10P=10 lM pioglitazone; 1PN=1 lM PNU-91325; and 10PN=10 lM PNU-91325. The color of each square
corresponds to 13C carbon ﬂux from stearate via various synthetic pathways of ribose, deoxyribose, lactate, glutamate of the TCA cycle and fatty
acids as percent of control-DMSO treated cultures. A color scheme indicating the intensity of changes in substrate ﬂux is provided in the bottom
of the ﬁgure. (DOR=deoxyribose; G6PDH=glucose 6-phosphate dehydrogenase; TPI=Triose-phosphate isomerase).
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various cells, a tracer study in vivo is warranted using
glucose and stearate tracer enriched diets in a wild type
and diabetic host in order to better understand the eﬀect
of a primarily mitochondrially acting TZD (via mito-
NEET?) plays in the regulation of long chain fatty acid
breakdown andmetabolism as compared to the currently
marketed TZDs that are more potent PPARc activators.
Finally, it is evident that many reported eﬀects of
TZDs are clearly independent of PPARs. A most recent
example is the demonstration that TZD inhibition of
iNOS expression does not require PPAR involvement
(Crosby et al., 2005). We suggest that many reported
eﬀects of TZD actions as being primarily mediated
through PPAR should be interpreted with caution and
that further investigation of the many secondary
pharmacological eﬀects associated with TZDs could
contribute to the development of new therapeutic
approaches to diabetes.
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